Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles by Raquel Bouça-Machado
Based on 2 articles published since 2008
||||

Between 2008 and 2019, Raquel Bouça-Machado wrote the following 2 articles about Parkinson Disease.
 
+ Citations + Abstracts
1 Review Palliative Care for Patients and Families With Parkinson's Disease. 2017

Bouça-Machado, Raquel / Titova, Nataliya / Chaudhuri, K Ray / Bloem, Bas R / Ferreira, Joaquim J. ·Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal; CNS-Campus Neurológico Sénior, Torres Vedras, Portugal. · Federal State Budgetary Educational Institution of Higher Education "N.I. Pirogov Russian National Research Medical University" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia. · National Parkinson Foundation International Centre of Excellence, Kings College and Kings College Hospital, London, United Kingdom; Maurice Wohl Clinical Neuroscience Institute, Kings College, London, United Kingdom; National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) and Dementia Unit at South London and Maudsley NHS Foundation Trust, London, United Kingdom. · Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. · Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal; CNS-Campus Neurológico Sénior, Torres Vedras, Portugal; Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal. Electronic address: joaquimjferreira@gmail.com. ·Int Rev Neurobiol · Pubmed #28554419.

ABSTRACT: Parkinson's disease is the second most common neurodegenerative disease worldwide. There is widespread consensus that Parkinson patients, their carers, and clinicians involved in their care would benefit from a fully integrated, need-based provision of palliative care. However, the concept of palliative care in Parkinson's disease is still poorly defined and, consequently, poorly implemented into daily clinical practice. A particular challenge is the gradually progressive nature of Parkinson's disease-with insidiously increasing disability-making it challenging to clearly define the onset of palliative care needs for Parkinson patients. As people with Parkinson's disease are now living longer than in the past, future research needs to develop a more robust evidence-based approach to clarify the disease events associated with increased palliative care needs, and to examine these, prospectively, in an integrated palliative care service. The modern palliative care outlook, termed "simultaneous care,",is no longer restricted to the final stage of disease. It involves incorporating a continuity of care, effective management of the chronic-palliative interface, and a multidisciplinary network of professionals working both in the community and in specialized clinics, with active involvement of caregivers. Although promising, there is still a need to demonstrate the effectiveness of palliative care for patients with Parkinson's disease.

2 Minor Neuromelanin magnetic resonance imaging of the substantia nigra in LRRK2-related Parkinson's disease. 2017

Correia Guedes, Leonor / Reimão, Sofia / Paulino, Patrícia / Nunes, Rita G / Bouça-Machado, Raquel / Abreu, Daisy / Gonçalves, Nilza / Soares, Tiago / Fabbri, Margherita / Godinho, Catarina / Pita Lobo, Patrícia / Neutel, Dulce / Quadri, Marialuisa / Coelho, Miguel / Rosa, Mario M / Campos, Jorge / Outeiro, Tiago F / Sampaio, Cristina / Bonifati, Vincenzo / Ferreira, Joaquim J. ·Department of Neurosciences and Mental Health, Neurology, Hospital de Santa Maria-CHLN, Lisbon, Portugal. · Clinical Pharmachology Unit, Instituto de Medicina Molecular, Lisbon, Portugal. · Neurological Imaging Department, Hospital de Santa Maria-CHLN, Lisbon, Portugal. · Instituto de Biofísica e Engenharia Biomédica, Faculty of Science, University of Lisbon, Portugal. · Faculty of Science and Technology, Nova University of Lisbon, Campus da Caparica, Portugal. · Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands. · Laboratory of Clinical Pharmachology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal. · CEDOC, Chronic Diseases Research Centre, Nova Medical School, Nova University of Lisbon, Lisboa, Portugal. · Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University Medical Center Gottingen, Germany. · Max Planck Institute for Experimental Medicine, Gottingen, Germany. · CNS-Campus Neurológico Sénior, Torres Vedras, Portugal. ·Mov Disord · Pubmed #28686310.

ABSTRACT: -- No abstract --